IPTeL Tracking ID: BS-MRDG-2018-110
The invention discloses a new therapeutic drug target which can be used to combat the causative agent of tuberculosis, leprosy and other non-tuberculous mycobacterial diseases. It is effective against the drug resistant strains of the pathogen and has limited side effects on
human body.
Area of technology: Life sciences/ Drug discovery
Technology Readiness Level (TRL): 2
BACKGROUND
- First line anti-tubercular drugs are prescribed for 6 months.
- High patient non-compliance has led to development of drug-resistant strains of mycobacteria.
- There is a need for highly targeted drug delivery with minimum side effects for mycobacterial diseases.
KEY FEATURES OF THE INVENTION
- The drug targets a highly conserved two component system (TCS) in bacterial signaling.
- Minimal side effects as the targeted signaling system is absent in eukaryotes.
- This targeting method can be used to combat tuberculosis, leprosy and other mycobacterial non-tuberculous diseases.
- Multiple assays based on TCS for screening inhibitors are also developed.
COMMERCIALIZATION
IISc has filed a provisional application for grant of patent in India. We are looking for potential licensees to commercialize this invention.
CONTACT DETAILS
- Mr. Venkat Rama Rao Adhikari
- Technology Licensing Manager
- Office of Intellectual Property and Technology Licensing
- E-mail: venkatadhikari@iisc.ac.in, Mobile: 8220260777